Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Candesartan cilexetil + chlorthalidone + amlodipine is a fixed-dose combination medication used for the treatment of hypertension. This triple therapy combines three antihypertensive agents with complementary mechanisms of action to provide comprehensive blood pressure control. Candesartan cilexetil is an angiotensin II receptor blocker (ARB) that inhibits the effects of angiotensin II, leading to vasodilation and reduced aldosterone-mediated sodium and water retention. Chlorthalidone is a thiazide-like diuretic that promotes renal excretion of sodium and water, reducing plasma volume and peripheral vascular resistance. Amlodipine is a calcium channel blocker that inhibits calcium influx into vascular smooth muscle cells, resulting in vasodilation and decreased blood pressure[1][5][8]. The combination targets multiple pathways involved in hypertension management, offering improved efficacy over monotherapy or dual therapy regimens[1][5]. It is primarily indicated for systemic arterial hypertension.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on candesartan cilexetil + chlorthalidone + amlodipine.